002422 Stock Overview
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Sichuan Kelun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.43 |
| 52 Week High | CN¥35.49 |
| 52 Week Low | CN¥21.60 |
| Beta | 0.065 |
| 1 Month Change | -3.76% |
| 3 Month Change | 13.00% |
| 1 Year Change | 6.18% |
| 3 Year Change | 64.49% |
| 5 Year Change | 29.60% |
| Change since IPO | 103.68% |
Recent News & Updates
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Nov 17
Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Recent updates
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Nov 17Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement
Sep 22Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?
Aug 16Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?
Jul 12Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares
Jun 11An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued
May 21Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem
May 02If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity
Mar 19Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Mar 04These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely
Feb 27Shareholder Returns
| 002422 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -4.0% | -1.9% | -1.2% |
| 1Y | 6.2% | -1.8% | 11.8% |
Return vs Industry: 002422 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002422 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002422 volatility | |
|---|---|
| 002422 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002422 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002422's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 19,798 | Sichuan Liu | www.kelun.com |
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers infusion products; oral medication and other dosage form; plastic ampoule and powder liquid dual chamber infusion bag; medical devices, such as infusion set, injection syringes, detained needles, nebulizer, and blood sampling; and over-the-counter products. The company was founded in 1996 and is based in Chengdu, the People's Republic of China.
Sichuan Kelun Pharmaceutical Co., Ltd. Fundamentals Summary
| 002422 fundamental statistics | |
|---|---|
| Market cap | CN¥48.28b |
| Earnings (TTM) | CN¥2.96b |
| Revenue (TTM) | CN¥22.50b |
16.3x
P/E Ratio2.1x
P/S RatioIs 002422 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002422 income statement (TTM) | |
|---|---|
| Revenue | CN¥22.50b |
| Cost of Revenue | CN¥10.85b |
| Gross Profit | CN¥11.65b |
| Other Expenses | CN¥8.68b |
| Earnings | CN¥2.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 51.76% |
| Net Profit Margin | 13.17% |
| Debt/Equity Ratio | 19.7% |
How did 002422 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield55%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 04:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sichuan Kelun Pharmaceutical Co., Ltd. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Liang Long | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Ziyu He | China International Capital Corporation Limited |